The Greater Cannabis Company, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
January 16, 2020 at 01:50 pm
Share
The Greater Cannabis Company, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced operating loss was USD 78,439 compared to USD 200,627 a year ago. Net loss was USD 126,430 compared to USD 955,322 a year ago. For the nine months, total revenue was USD 2,620 compared to USD 95,375 a year ago. Operating loss was USD 330,593 compared to USD 114,751 a year ago. Net loss was USD 552,558 compared to USD 863,543 a year ago. Basic loss per share was USD 0.02 compared to USD 0.03 a year ago.
The Greater Cannabis Company, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. The Company conducts clinical studies on and commercialize the cannabinoid-based therapeutic and concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions. Its delivery technologies use a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides needle free, intra-oral systemic drug delivery.
THE GREATER CANNABIS COMPANY, INC. 
